|
1
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009.
View Article : Google Scholar
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
Statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
3
|
Wainberg ZA, Anghel A, Desai AJ, et al:
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively
inhibits HER2-amplified human gastric cancer cells and is
synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res.
16:1509–1519. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Engelman JA: Targeting PI3K signalling in
cancer: opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li VS, Wong CW, Chan TL, et al: Mutations
of PIK3CA in gastric adenocarcinoma. BMC Cancer. 5:292005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Velho S, Oliveira C, Ferreira A, et al:
The prevalence of PIK3CA mutations in gastric and colon cancer. Eur
J Cancer. 41:1649–1654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Byun DS, Cho K, Ryu BK, et al: Frequent
monoallelic deletion of PTEN and its reciprocal associatioin with
PIK3CA amplification in gastric carcinoma. Int J Cancer.
104:318–327. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Staal SP: Molecular cloning of the akt
oncogene and its human homologues AKT1 and AKT2: amplification of
AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci
USA. 84:5034–5037. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee KH, Hur HS, Im SA, et al: RAD001 shows
activity against gastric cancer cells and overcomes 5-FU resistance
by downregulating thymidylate synthase. Cancer Lett. 299:22–28.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Osaki M, Kase S, Adachi K, Takeda A,
Hashimoto K and Ito H: Inhibition of the PI3K-Akt signaling pathway
enhances the sensitivity of Fas-mediated apoptosis in human gastric
carcinoma cell line, MKN-45. J Cancer Res Clin Oncol. 130:8–14.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fuereder T, Jaeger-Lansky A, Hoeflmayer D,
et al: mTOR inhibition by everolimus counteracts VEGF induction by
sunitinib and improves anti-tumor activity against gastric cancer
in vivo. Cancer Lett. 296:249–256. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Brien C, Wallin JJ, Sampath D, et al:
Predictive biomarkers of sensitivity to the phosphatidylinositol 3'
kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin
Cancer Res. 16:3670–3683. 2010.
|
|
14
|
Engelman JA, Chen L, Tan X, et al:
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D
and PIK3CA H1047R murine lung cancers. Nat Med. 14:1351–1356. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ihle NT, Lemos R Jr, Wipf P, et al:
Mutations in the phosphatidylinositol-3-kinase pathway predict for
antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is
a dominant predictor for resistance. Cancer Res. 69:143–150. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gough DJ, Corlett A, Schlessinger K,
Wegrzyn J, Larner AC and Levy DE: Mitochondrial STAT3 supports
Ras-dependent oncogenic transformation. Science. 324:1713–1716.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu H, Kortylewski M and Pardoll D:
Crosstalk between cancer and immune cells: role of STAT3 in the
tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
To KF, Chan MW, Leung WK, et al:
Constitutional activation of IL-6-mediated JAK/STAT pathway through
hypermethylation of SOCS-1 in human gastric cancer cell line. Br J
Cancer. 91:1335–1341. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hedvat M, Huszar D, Herrmann A, et al: The
JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and
oncogenesis in solid tumors. Cancer Cell. 16:487–497. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nelson EA, Walker SR, Kepich A, et al:
Nifuroxazide inhibits survival of multiple myeloma cells by
directly inhibiting STAT3. Blood. 112:5095–5102. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ku JL and Park JG: Biology of SNU cell
lines. Cancer Res Treat. 37:1–19. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wan X, Harkavy B, Shen N, Grohar P and
Helman LJ: Rapamycin induces feedback activation of Akt signaling
through an IGF-1R-dependent mechanism. Oncogene. 26:1932–1940.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
O'Reilly KE, Rojo F, She QB, et al: mTOR
inhibition induces upstream receptor tyrosine kinase signaling and
activates Akt. Cancer Res. 66:1500–1508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sos ML, Fischer S, Ullrich R, et al:
Identifying genotype-dependent efficacy of single and combined
PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci
USA. 106:18351–18356. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Okuzumi T, Fiedler D, Zhang C, et al:
Inhibitor hijacking of Akt activation. Nat Chem Biol. 5:484–493.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han EK, Leverson JD, McGonigal T, et al:
Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation
independent of mTORC1 inhibition. Oncogene. 26:5655–5661. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carracedo A, Ma L, Teruya-Feldstein J, et
al: Inhibition of mTORC1 leads to MAPK pathway activation through a
PI3K-dependent feedback loop in human cancer. J Clin Invest.
118:3065–3074. 2008.PubMed/NCBI
|
|
29
|
Gupta S, Ramjaun AR, Haiko P, et al:
Binding of ras to phosphoinositide 3-kinase p110α is required for
ras-driven tumorigenesis in mice. Cell. 129:957–968. 2007.
|
|
30
|
Wee S, Jagani Z, Xiang KX, et al: PI3K
pathway activation mediates resistance to MEK inhibitors in KRAS
mutant cancers. Cancer Res. 69:4286–4293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Halilovic E, She QB, Ye Q, et al: PIK3CA
mutation uncouples tumor growth and cyclin D1 regulation from
MEK/ERK and mutant KRAS signaling. Cancer Res. 70:6804–6814. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
She QB, Solit DB, Ye Q, O'Reilly KE, Lobo
J and Rosen N: The BAD protein integrates survival signaling by
EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor
cells. Cancer Cell. 8:287–297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: a leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yokogami K, Wakisaka S, Avruch J and
Reeves SA: Serine phosphorylation and maximal activation of STAT3
during CNTF signaling is mediated by the rapamycin target mTOR.
Curr Biol. 10:47–50. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou J, Wulfkuhle J, Zhang H, et al:
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer
stem-like cells is required for viability and maintenance. Proc
Natl Acad Sci USA. 104:16158–16163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Carriere A, Cargnello M, Julien LA, et al:
Oncogenic MAPK signaling stimulates mTORC1 activity by promoting
RSK-mediated raptor phosphorylation. Curr Biol. 18:1269–1277. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Alimonti A, Carracedo A, Clohessy JG, et
al: Subtle variations in Pten dose determine cancer susceptibility.
Nat Genet. 42:454–458. 2010. View
Article : Google Scholar : PubMed/NCBI
|
